Eleclazine (hydrochloride)

Eleclazine (GS 6615) hydrochloride is a selective cardiac late sodium current inhibitor and a weak inhibitor of potassium current with IC50 value of [1][2][3].

Product Specifications

CAS Number

[1448754-43-5]

Product Name Alternative

GS 6615 (hydrochloride)

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Potassium Channel; Sodium Channel

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/Eleclazine-hydrochloride.html

Concentration

10mM

Purity

99.66

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C1N(CC2=NC=CC=N2)CCOC3=CC=C(C4=CC=C(OC(F)(F)F)C=C4)C=C13.[H]Cl

Molecular Formula

C21H17ClF3N3O3

Molecular Weight

451.83

Precautions

H302, H315, H319, H335

References & Citations

[1]Rajamani S et al. The novel late Na+ current inhibitor, GS-6615 (eleclazine) and its anti-arrhythmic effects in rabbit isolated heart preparations. Br J Pharmacol. 2016 Jul 23.|[2]Bacic D, et al. Eleclazine, an inhibitor of the cardiac late sodium current, is superior to flecainide in suppressing catecholamine-induced ventricular tachycardia and T-wave alternans in an intact porcine model. Heart Rhythm. 2017 Mar;14 (3) :448-454.|[3]Potet F, Egecioglu DE, Burridge PW, George AL Jr. GS-967 and Eleclazine Block Sodium Channels in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes. Mol Pharmacol. 2020 Nov;98 (5) :540-547.